GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PAVmed Inc (NAS:PAVM) » Definitions » Gross Profit

PAVmed (PAVmed) Gross Profit : $-3.80 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is PAVmed Gross Profit?

PAVmed's gross profit for the three months ended in Mar. 2024 was $-0.73 Mil. PAVmed's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.80 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. PAVmed's gross profit for the three months ended in Mar. 2024 was $-0.73 Mil. PAVmed's Revenue for the three months ended in Mar. 2024 was $1.01 Mil. Therefore, PAVmed's Gross Margin % for the quarter that ended in Mar. 2024 was -72.67%.

PAVmed had a gross margin of -72.67% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 10 years, the highest Gross Margin % of PAVmed was -17.00%. The lowest was -858.62%. And the median was -161.83%.


PAVmed Gross Profit Historical Data

The historical data trend for PAVmed's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PAVmed Gross Profit Chart

PAVmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.09 -3.24 -3.97

PAVmed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.90 -1.52 -0.99 -0.56 -0.73

Competitive Comparison of PAVmed's Gross Profit

For the Medical Devices subindustry, PAVmed's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PAVmed's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's Gross Profit distribution charts can be found below:

* The bar in red indicates where PAVmed's Gross Profit falls into.



PAVmed Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

PAVmed's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=2.452 - 6.42
=-3.97

PAVmed's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=1.01 - 1.744
=-0.73

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.80 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

PAVmed's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=-0.73 / 1.01
=-72.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


PAVmed  (NAS:PAVM) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

PAVmed had a gross margin of -72.67% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


PAVmed Gross Profit Related Terms

Thank you for viewing the detailed overview of PAVmed's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


PAVmed (PAVmed) Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard and the Veris Cancer Care Platform.
Executives
Michael J Glennon director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Brian J. Deguzman officer: Chief Medical Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Dennis M Mcgrath officer: President & CFO C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Lishan Aklog director, 10 percent owner, officer: Chairman and CEO 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Joan B Harvey director ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Timothy E Baxter director ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Matthew Sirovich 10 percent owner C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123
Ira Scott Greenspan director 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Joshua R Lamstein director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170